Research Topics
Bayer Pays Ardea $7.5M
May 30, 2012 11:15 am | News | CommentsArdea Biosciences has received a $7.5 million payment from Bayer HealthCare, its partner on an experimental cancer drug, BAY 86-9766, which Ardea discovered.
CLP1001 Improves HF Symptoms
May 29, 2012 11:12 am | News | CommentsSorbent Therapeutics Inc. said that CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo in a Phase 2a clinical study.
LDX Stays Effective in ADHD
May 29, 2012 11:04 am | News | CommentsA Phase 3 study has demonstrated the long-term maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Positive Results in Linagliptin Trial
May 29, 2012 10:42 am | News | CommentsBoehringer Ingelheim and Eli Lilly announced Phase 3 study results for linagliptin, which showed a significant HbA1c reduction of 0.88% compared to 0.24% in the placebo group.
APD421 Reduces Nausea, Vomiting
May 29, 2012 10:35 am | News | CommentsAcacia Pharma announces positive results from its double-blind Phase 2 study of APD421, in the prevention of post-operative nausea and vomiting.
Boehringer Ingelheim Releases Phase 2 Results
May 25, 2012 10:12 am | News | CommentsBoehringer Ingelheim announced results from a Phase 2 study evaluating tiotropium delivered daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.
Enrollment Wraps Up in MOR208 Study
May 25, 2012 10:04 am | News | CommentsMorphoSys AG and Xencor Inc. announced the successful completion of patient enrollment in the Phase 1 clinical trial evaluating MOR208.
Kinase Assay
May 24, 2012 11:37 am | Product Releases | CommentsCisbio Bioassays has added three kinase assays to its cell-based kinase screening platform for the study of different signaling pathways in drug discovery research.
HyperAcute Pancreas Meets Trial Endpoint
May 24, 2012 10:57 am | News | CommentsHyperAcute Pancreas is currently being evaluated in a multi-institution, randomized, Phase 3 clinical trial under a Special Protocol Assessment with the FDA.
Tivantinib Meets Study Endpoint
May 23, 2012 9:49 am | News | CommentsArQule Inc. and Daiichi Sankyo Co. Ltd. announced that a Phase 2 trial using tivantinib as a second-line treatment in hepatocellular carcinoma met its primary endpoint.
Positive Results from Tesetaxel Study
May 23, 2012 9:42 am | News | CommentsGenta Incorporated announced results from its Phase 2 clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer.
2012 CRO-CMO Directory - Drug Discovery Services
May 22, 2012 6:36 pm | Articles | CommentsFind contract research organizations (CROs) for Drug Discovery Services in the 2012 CRO/CMO Directory, from Drug Discovery & Development magazine.
2012 CRO-CMO Directory - Preclinical Services
May 22, 2012 5:49 pm | Articles | CommentsFind contract research organizations (CROs) for Preclinical Services in the 2012 CRO/CMO Directory, from Drug Discovery & Development magazine.
Protein Tag
May 22, 2012 11:51 am | Product Releases | CommentsSandia Biotech's split-Green Fluorescent Protein technology allows researchers to analyze proteins and peptides with greater accuracy and fewer steps than current methods.
Positive Results from CPP-115 Trial
May 22, 2012 11:17 am | News | CommentsCatalyst Pharmaceutical Partners Inc. announced positive results from a Phase 1a study to evaluate the safety, tolerability and pharmacokinetic profile of CPP-115.
NovaBay Begins Enrolling NVC-422 Patients
May 22, 2012 11:09 am | News | CommentsNovaBay Pharmaceuticals Inc. has enrolled the first patients in its Phase 2b clinical study to evaluate its lead compound NVC-422, for treating adenoviral conjunctivitis.
Nexavar Flunks Lung Cancer Trial
May 22, 2012 10:29 am | News | CommentsA cancer treatment from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc. failed to improve overall survival in patients with advanced cases of lung cancer.
Drug Combo Tackling Solid Tumors
May 18, 2012 11:09 am | News | CommentsCancer Research UK's Drug Development Office has begun a trial of a drug combination in patients with advanced solid tumors and in patients with non-small cell lung cancer.
Phase 2 Results for EP-101 Positive
May 18, 2012 10:56 am | News | CommentsElevation Pharmaceuticals Inc. announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease.
Positive Results for Theraclone Flu Treatment
May 17, 2012 11:25 am | News | CommentsTheraclone Sciences Inc. announced positive data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, for the treatment of influenza A infections.
Ark Readies Phase 2 Study
May 17, 2012 11:00 am | News | CommentsArk Therapeutics Group plc has completed the dose ranging Phase 1 section of the academic study of Ark’s VEGF-D adenoviral vector treatment for refractory angina.
Natural Product Purification of Lycopene and β‐Carotene Using Flash Column Sample Clean‐up Prior to High Pressure Normal Phase Chromatography on the Gilson PLC 2020
May 16, 2012 3:25 pm | White Papers | CommentsPurifying low level compounds, such as those typically isolated from natural products, is an area of growing interest for the purpose of discovering new chemical entities.
Pipelines Under Pressure Take New Paths
May 15, 2012 2:58 pm | by Ted Agres, Contributing Editor | Articles | CommentsIn order to foster innovation, reduce costs, and halt the erosion of revenue, major pharmaceutical companies are exploring a range of new and emerging research arrangements.
Faster Pharmacokinetics
May 15, 2012 12:45 pm | by Mike May, Contributing Editor | Articles | CommentsPharmacokinetics plays a crucial role in a compound’s efficacy and safety and to characterize the pharmacokinetics of a compound, accurate measurements are needed.
GAL-021 Counteracts Respiratory Depression
May 15, 2012 10:49 am | News | CommentsGalleon Pharmaceuticals announced that GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase 1 study.
